Early access
Sign in
Taking people in United StatesPhase 1

Tests SynKIR-110 cell therapy in advanced ovarian cancer, bile duct cancer, or mesothelioma

Tests SynKIR-110, a patient's own modified T cells, in adults with advanced mesothelin-expressing cancers.

Key facts

Who runs it
Verismo Therapeutics
Where
Houston, Madison, Philadelphia, Tampa, and Westwood, United StatesSee the 5 sites
Trial code
Registry title
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Status
Recruiting
Phase
Phase 1
People taking part
42 people, planned
Started
30 Mar 2023
Expected to end
Dec 2027
Type of study
Interventional
Treatments tested
  • SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Record updated
24 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced ovarian cancer, cholangiocarcinoma or mesothelioma that came back or got worse after earlier treatment. It tests a single dose of SynKIR-110 T-cell therapy.

Age
18 years or older
Sex
All sexes can join
Disease stage
Advanced ovarian, primary peritoneal, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) that came back or relapsed. At least 1 lesion that can be measured. Performance status (ECOG) 0 to 1.
Earlier treatment
At least 1 earlier line of systemic therapy for advanced disease. No earlier gene-engineered T cell therapy.
Biomarker or test result
The trial title names mesothelin-expressing cancer. The criteria give no test result requirement.

Main reasons for not taking part

  • Other active invasive cancers, unless free of disease for 5 years after treatment
  • History of T or B cell cancer
  • Sarcomatoid or biphasic mesothelioma
  • Active hepatitis B, active hepatitis C, or any HIV infection
  • Active autoimmune disease

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1 prior line of systemic therapy for advanced disease
  • Adult 18 years of age or older
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Has at least 1 measurable lesion by iRECIST for ovarian cancer or cholangiocarcinoma or lesions measurable for mRECIST for mesothelioma
  • Satisfactory Blood coagulation parameters
  • Satisfactory organ and bone marrow function

Who cannot take part

  • History of T or B cell malignancies or previous gene-engineered T cell therapies
  • Active invasive cancers other than mesothelioma, cholangiocarcinoma, and ovarian unless surgically and medically cured without evidence of recurrent disease for 5 years
  • Have acquired hereditary, congenital immunodeficiency or have recognized immunodeficiency disease
  • Active hepatitis B, active hepatitis C, or any HIV infection at the time of screening
  • Active autoimmune disease
  • Sarcomatoid/biphasic mesothelioma
  • Pulmonary exclusions

Where in United States

  • MD Anderson Cancer CenterHouston, United StatesContact: Zheng ZhangTaking people
  • University of Wisconsin Carbone Cancer CenterMadison, United StatesContact: Cancer ConnectTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Andrea StandishTaking people
  • Moffitt Cancer CenterTampa, United StatesContact: Ashley O'Neil, MPH, LSSWB, CCRCTaking people
  • University of Kansas Cancer CenterWestwood, United StatesNo longer taking part

About the trial

What the trial wants to find out

This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.

The group in the trial

  • SynKIR-110Treatment being tested

    Single dose gravity drip IV administration

    Treatment: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
Plain-language title
Tests SynKIR-110 cell therapy in advanced ovarian cancer, bile duct cancer, or mesotheliomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
24 June 2026